Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger ...

Please provide your email address to receive an email when new articles are posted on . Patients with sickle cell disease and beta-thalassemia reported substantial improvements in quality of life ...

More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...

CEL-SCI Corporation (NYSE:CVM) shares tumbled 38.19% in after-hours trading to $8.06 on Tuesday following the cancer immunotherapy company’s announcement of a $10 million public offering priced below ...

Researchers from Trina Solar and China’s Nanchang University claim to have verified that back-contact solar modules outperform TOPCon modules only when fewer than three cells in a substring are shaded ...

Obecabtagene autoleucel showed effective outcomes in both younger and older adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with similar remission rates and chimeric antigen ...

GameSpot may get a commission from retail offers. The spectacular new Fortnite Superman. As you can see, we've got a cel-shaded look with a rather unique version of the Superman logo with the S on a ...

Learn how to install Roblox shaders using ReShade with this step-by-step tutorial for enhanced graphics and improved gaming experience.

Cema-cel demonstrated durable responses in relapsed/refractory large B-cell lymphoma, with high overall and complete response rates comparable to autologous CAR-T therapies. The safety profile of cema ...

As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed ...

The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...